Bavarian Nordic A/S (BAVA.CO)
DKK 198.95
(2.82%)
DKK 198.95
(2.82%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.64 Billion DKK | 78.85% |
| 2022 | 919.07 Million DKK | 91.46% |
| 2021 | 480.04 Million DKK | -7.88% |
| 2020 | 521.08 Million DKK | 417.14% |
| 2019 | 100.76 Million DKK | -0.12% |
| 2018 | 100.88 Million DKK | -24.74% |
| 2017 | 134.04 Million DKK | -38.24% |
| 2016 | 217.05 Million DKK | 34.76% |
| 2015 | 161.07 Million DKK | 32.19% |
| 2014 | 121.84 Million DKK | -47.85% |
| 2013 | 233.65 Million DKK | 1.94% |
| 2012 | 229.2 Million DKK | 4.69% |
| 2011 | 218.92 Million DKK | 80.26% |
| 2010 | 121.45 Million DKK | -50.72% |
| 2009 | 246.46 Million DKK | 296.24% |
| 2008 | 62.2 Million DKK | 435.25% |
| 2007 | 11.62 Million DKK | -9.79% |
| 2006 | 12.88 Million DKK | 33.78% |
| 2005 | 9.62 Million DKK | -76.51% |
| 2004 | 40.99 Million DKK | 8148.89% |
| 2003 | 497 Thousand DKK | -99.2% |
| 2002 | 61.93 Million DKK | 1169.58% |
| 2001 | 4.87 Million DKK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 1.99 Billion DKK | 11.77% |
| 2024 Q1 | 1.78 Billion DKK | 8.47% |
| 2023 Q4 | 1.64 Billion DKK | -5.53% |
| 2023 Q2 | 1.5 Billion DKK | 25.38% |
| 2023 Q1 | 1.2 Billion DKK | 30.9% |
| 2023 FY | 1.64 Billion DKK | 78.85% |
| 2023 Q3 | 1.73 Billion DKK | 15.35% |
| 2022 Q1 | 603.57 Million DKK | 25.73% |
| 2022 FY | 919.07 Million DKK | 91.46% |
| 2022 Q4 | 919.07 Million DKK | 55.46% |
| 2022 Q3 | 591.21 Million DKK | 14.04% |
| 2022 Q2 | 518.4 Million DKK | -14.11% |
| 2021 Q3 | 553.27 Million DKK | -17.1% |
| 2021 Q1 | 552.83 Million DKK | 6.09% |
| 2021 Q2 | 667.44 Million DKK | 20.73% |
| 2021 FY | 480.04 Million DKK | -7.88% |
| 2021 Q4 | 480.04 Million DKK | -13.24% |
| 2020 Q4 | 521.08 Million DKK | 45.77% |
| 2020 FY | 521.08 Million DKK | 417.14% |
| 2020 Q1 | 186.76 Million DKK | 85.35% |
| 2020 Q2 | 154.59 Million DKK | -17.22% |
| 2020 Q3 | 357.46 Million DKK | 131.23% |
| 2019 Q2 | 119.42 Million DKK | 23.76% |
| 2019 Q4 | 100.76 Million DKK | 0.14% |
| 2019 Q3 | 100.61 Million DKK | -15.74% |
| 2019 FY | 100.76 Million DKK | -0.12% |
| 2019 Q1 | 96.49 Million DKK | -4.35% |
| 2018 Q1 | 135.55 Million DKK | 1.12% |
| 2018 Q3 | 153.12 Million DKK | -5.46% |
| 2018 Q4 | 100.88 Million DKK | -34.11% |
| 2018 FY | 100.88 Million DKK | -24.74% |
| 2018 Q2 | 161.97 Million DKK | 19.5% |
| 2017 Q2 | 222.7 Million DKK | -13.31% |
| 2017 Q4 | 134.04 Million DKK | 12.76% |
| 2017 FY | 134.04 Million DKK | -38.24% |
| 2017 Q1 | 256.88 Million DKK | 18.35% |
| 2017 Q3 | 118.88 Million DKK | -46.62% |
| 2016 Q3 | 223.46 Million DKK | -14.95% |
| 2016 FY | 217.05 Million DKK | 34.76% |
| 2016 Q4 | 217.05 Million DKK | -2.87% |
| 2016 Q2 | 262.74 Million DKK | 42.19% |
| 2016 Q1 | 184.78 Million DKK | 14.72% |
| 2015 Q4 | 161.07 Million DKK | -27.1% |
| 2015 Q1 | 212.1 Million DKK | 74.07% |
| 2015 Q2 | 207.4 Million DKK | -2.22% |
| 2015 FY | 161.07 Million DKK | 32.19% |
| 2015 Q3 | 220.95 Million DKK | 6.54% |
| 2014 FY | 121.84 Million DKK | -47.85% |
| 2014 Q1 | 204.6 Million DKK | -12.43% |
| 2014 Q2 | 236.3 Million DKK | 15.49% |
| 2014 Q3 | 232.8 Million DKK | -1.48% |
| 2014 Q4 | 121.84 Million DKK | -47.66% |
| 2013 Q3 | 217.7 Million DKK | -6.65% |
| 2013 FY | 233.65 Million DKK | 1.94% |
| 2013 Q1 | 184.6 Million DKK | -19.46% |
| 2013 Q2 | 233.2 Million DKK | 26.33% |
| 2013 Q4 | 233.65 Million DKK | 7.33% |
| 2012 Q1 | 273.1 Million DKK | 24.75% |
| 2012 Q4 | 229.2 Million DKK | -10.26% |
| 2012 Q3 | 255.4 Million DKK | -2.78% |
| 2012 FY | 229.2 Million DKK | 4.69% |
| 2012 Q2 | 262.7 Million DKK | -3.81% |
| 2011 Q2 | 214.8 Million DKK | 46.02% |
| 2011 Q1 | 147.1 Million DKK | 21.12% |
| 2011 Q4 | 218.92 Million DKK | -20.45% |
| 2011 Q3 | 275.2 Million DKK | 28.12% |
| 2011 FY | 218.92 Million DKK | 80.26% |
| 2010 Q1 | 237.8 Million DKK | -3.52% |
| 2010 Q4 | 121.45 Million DKK | -0.53% |
| 2010 Q3 | 122.1 Million DKK | -40.06% |
| 2010 FY | 121.45 Million DKK | -50.72% |
| 2010 Q2 | 203.7 Million DKK | -14.34% |
| 2009 Q4 | 246.46 Million DKK | 0.0% |
| 2009 FY | 246.46 Million DKK | 296.24% |
| 2008 FY | 62.2 Million DKK | 435.25% |
| 2007 FY | 11.62 Million DKK | -9.79% |
| 2006 FY | 12.88 Million DKK | 33.78% |
| 2005 FY | 9.62 Million DKK | -76.51% |
| 2004 FY | 40.99 Million DKK | 8148.89% |
| 2003 FY | 497 Thousand DKK | -99.2% |
| 2002 FY | 61.93 Million DKK | 1169.58% |
| 2001 FY | 4.87 Million DKK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ALK-Abelló A/S | 1.42 Billion DKK | -15.512% |
| Genmab A/S | 57 Million DKK | -2783.747% |
| Gubra A/S | -403.98 Million DKK | 506.876% |
| Novo Nordisk A/S | 31.81 Billion DKK | 94.833% |
| Orphazyme A/S | -1099.00 DKK | 149566615.014% |
| Pharma Equity Group A/S | 1000.00 DKK | -164373500.0% |
| Zealand Pharma A/S | 7.93 Million DKK | -20615.009% |